|
Comparison of Immunoassays Designed to Measure Immune Response to HPV Vaccination: The Serology Methods Study, Phase II (SMS-II)
|
Research Initiative
|
CDC
|
NCI
|
This work serves as an expansion to the original serology methods study (SMS I) that evaluated the validity and reproducibility of measures of the vaccine induced HPV16/18 antibody response by several HPV serologic assays. Now, with the investigation of single-dose regimens of the nonavalent HPV vaccine (9vHPV), it is necessary to expand this assessment to the additional seven genotypes included in the 9vHPV vaccine formulation. Further, as most of the assays evaluated in the first study were single-plex assays, performance characteristics for the HPV 16 and 18 antibody detection in multiplex assays testing of nine HPV types will be confirmed. The second phase of the methods work, the SMS II, continues to focus on single-dose HPV vaccine recipients as they have, on average, lower antibody levels compared to people who receive multi-dose regimens.
|
|
Computational Toxicology Analysis
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
The Center for Drug Evaluation and Research at the Food and Drug Administration evaluates molecular structures for potential toxicities provided by NIDA using software platforms developed for this purpose. This interagency agreement stimulates the development of predictive software models that benefit drug discovery programs at both agencies.
|
|
Consumer Product Chemical Exposures in Pregnancy and Their Cumulative Impact on Disorders of Fetal Growth
|
Research Initiative
|
CDC
|
NIEHS
|
The purpose of this collaboration is to characterize exposure to organophosphate (OP) flame retardants and pesticides among pregnant women by measuring OP flame retardants and dialkyl phosphate metabolites (DAPs) in urine samples from 3 visits in pregnancy. We will examine associations between these markers and fetal growth as well as inflammation biomarkers.
|
|
Contraceptive Technology Donor Coordination Group
|
Resource Development
|
Not Reported
|
NICHD
|
Collaboration between USAID, NICHD and the Bill & Melinda Gates Foundation to coordinate interagency and foundation activities related to contraceptive development.
|
|
Coordinated Sentinel Surveillance and Discovery Program for Emerging Human Pathogens
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
OD/DPCPSI/OSC
|
Ongoing detection and discovery (Khoj in Hindi) for surveillance of emerging and reemerging human pathogens are central to public health preparedness and outbreak detection and response at a regional, national, and international level. This surveillance is dependent on microbiological diagnoses from individual patients and, based on the type of infection, up to 60% of patients with serious infections may not have a pathogen identified even after extensive testing in the microbiology laboratory. There is no nationwide threat-agnostic surveillance system for emerging or reemerging human pathogens. Developing a coordinated sentinel surveillance system to apply advanced molecular methods (e.g., “shotgun metagenomics”) to clinical specimens from people with severe illness and who are negative by commercially available diagnostic assays would provide a foundation for systematic emerging pathogen discovery at an unprecedented scale, and significantly strengthen proactive preparedness and response capabilities. An interagency steering committee is in place to facilitate internal and external partnerships to conduct the project activities and establish a foundation of leadership and strategy for a national, coordinated sentinel surveillance system for emerging and reemerging human pathogens. Project activities that this steering committee will inform include: 1) developing the approach and scope of a targeted landscape analysis to identify existing activities and gaps in coordination; 2) establishing an information sharing mechanism to increase collaboration; 3) piloting receipt of specimens for external laboratories and analysis with shotgun metagenomic sequencing; and 4) examining the feasibility of accessing CDC resources to setup control panels. RTI International (RTI) will support advancing the Bio- Khoj project with CDC and the steering committee.
|
|
Coordinating Council on Access and Mobility
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, CDC, CMS, HRSA, IHS, OASH, SAMHSA
|
NIA
|
The Coordinating Council on Access and Mobility (CCAM) is a Federal interagency council that works to coordinate funding and provide expertise on human services transportation for three targeted populations: people with disabilities, older adults, and individuals of low income.
|
|
Council of Federal Executive Secretariats
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, OIG
|
OD/IMOD/ES
|
Representatives from Executive Secretariats across government meet monthly for information exchange, knowledge sharing, and to receive updates from the White House Office of Presidential Correspondence Office.
|
|
Country Work in Cancer Research and Cancer Control Planning Strengthening – Kenya
|
Resource Development
|
CDC
|
FIC, NCI, NIAID
|
Kenya has an estimated population of approximately 53 million (World Bank). Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. Other collaborative activities: research initiative, partnership
|
|
Covid Serology Research and Results Tracker (SeroHub)
|
Resource Development
|
CDC
|
NCI, NIAID
|
The Covid-19 Serology Research Tracking System and Dasboard serves as a research resource to the NCI/NIAID/CDC and to the broader research community to monitor seroprevalence. Project is slated to end in August 2024. DCEG contact is Dr. Stephen Chanock.
|
|
COVID-19 and Influenza Scenario Modeling Hubs
|
Research Initiative
|
CDC
|
FIC, NIGMS
|
Collaboration between NIH, CDC and academia for disease projections. From weather to infectious diseases, it has been shown that synergizing results from multiple models gives more reliable projections than any one model alone. The COVID-19 Scenario Modeling Hub is a collaborative effort between multiple government agencies and academic institutions to harmonize COVID-19 projections in the United States and facilitate planning and decision making at a 3-12 month time scale. Since December 2020, the COVID19 scenario modeling hub has released 12 rounds of projections on issues as varied as the impact of the vaccination program, non-pharmaceutical interventions, waning immunity, and new variants on the trajectory of cases, hospitalizations and deaths across the US. The most recent set of projections addresses the impact of Omicron. In each round of projections, a set of 4 scenarios are identified to allow alignment of model projections for collective insights. Scenarios are designed in consultation with academic modeling teams, NIH and the CDC. Between 6 and 10 models have contributed to each round. All projections are made publicly available via the COVID-19 scenario modeling hub github and website. After each round, a report summarizing key results is shared with decision-makers and public health stakeholders. There has been substantial media coverage on this effort and results have been used by CDC/ACIP to guide COVID19 vaccine recommendations. The hub expanded in 2022 to generate influenza projections. This study builds on long-standing efforts led by the Fogarty International Center's in-house research division to develop computational approaches to mitigate pandemic risk and foster collaborative network in disease modeling. This effort extends a prior collaboration titled the Multinational Influenza Seasonal Mortality Study (MISMS) to assess the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications.
|